世界の後期慢性腎臓病治療薬市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Late Stage Chronic Kidney Disease Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12423 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、後期慢性腎臓病治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。後期慢性腎臓病治療薬の種類別市場規模（カルシウム模倣薬、ビタミンDステロール、カリウム結合剤、その他）、用途別市場規模（病院薬局、オンライン薬局、小売薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・後期慢性腎臓病治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：AbbVie、Amgen、Ardelyx、AstraZeneca、Deltanoid、Akebia Therapeutics、Kyowa Hakko Kirin、OPKO Health、Vifor Pharma、Sanofi、Shield Therapeutics、Shire、Spectrum、ZS Pharma ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：カルシウム模倣薬、ビタミンDステロール、カリウム結合剤、その他 ・用途別分析2016年-2026年：病院薬局、オンライン薬局、小売薬局 ・後期慢性腎臓病治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・後期慢性腎臓病治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・後期慢性腎臓病治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・後期慢性腎臓病治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・後期慢性腎臓病治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Late Stage Chronic Kidney Disease Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Late Stage Chronic Kidney Disease Drugs size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Late Stage Chronic Kidney Disease Drugs market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Late Stage Chronic Kidney Disease Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Calcimimetics
Vitamin D Sterols
Potassium Binders
Others

Market segment by Application, can be divided into
Hospital Pharmacies
Online Pharnacies
Retail Pharmacies

Market segment by players, this report covers
AbbVie
Amgen
Ardelyx
AstraZeneca
Deltanoid
Akebia Therapeutics
Kyowa Hakko Kirin
OPKO Health
Vifor Pharma
Sanofi
Shield Therapeutics
Shire
Spectrum
ZS Pharma

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Late Stage Chronic Kidney Disease Drugs
1.2 Classification of Late Stage Chronic Kidney Disease Drugs by Type
1.2.1 Overview: Global Late Stage Chronic Kidney Disease Drugs Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Type in 2020
1.2.3 Calcimimetics
1.2.4 Vitamin D Sterols
1.2.5 Potassium Binders
1.2.6 Others
1.3 Global Late Stage Chronic Kidney Disease Drugs Market by Application
1.3.1 Overview: Global Late Stage Chronic Kidney Disease Drugs Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital Pharmacies
1.3.3 Online Pharnacies
1.3.4 Retail Pharmacies
1.4 Global Late Stage Chronic Kidney Disease Drugs Market Size & Forecast
1.5 Global Late Stage Chronic Kidney Disease Drugs Market Size and Forecast by Region
1.5.1 Global Late Stage Chronic Kidney Disease Drugs Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Late Stage Chronic Kidney Disease Drugs Market Size by Region, (2016-2021)
1.5.3 North America Late Stage Chronic Kidney Disease Drugs Market Size and Prospect (2016-2026)
1.5.4 Europe Late Stage Chronic Kidney Disease Drugs Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size and Prospect (2016-2026)
1.5.6 South America Late Stage Chronic Kidney Disease Drugs Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Late Stage Chronic Kidney Disease Drugs Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Late Stage Chronic Kidney Disease Drugs Market Drivers
1.6.2 Late Stage Chronic Kidney Disease Drugs Market Restraints
1.6.3 Late Stage Chronic Kidney Disease Drugs Trends Analysis
2 Company Profiles
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie Late Stage Chronic Kidney Disease Drugs Product and Solutions
2.1.4 AbbVie Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 AbbVie Recent Developments and Future Plans
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Late Stage Chronic Kidney Disease Drugs Product and Solutions
2.2.4 Amgen Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Amgen Recent Developments and Future Plans
2.3 Ardelyx
2.3.1 Ardelyx Details
2.3.2 Ardelyx Major Business
2.3.3 Ardelyx Late Stage Chronic Kidney Disease Drugs Product and Solutions
2.3.4 Ardelyx Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Ardelyx Recent Developments and Future Plans
2.4 AstraZeneca
2.4.1 AstraZeneca Details
2.4.2 AstraZeneca Major Business
2.4.3 AstraZeneca Late Stage Chronic Kidney Disease Drugs Product and Solutions
2.4.4 AstraZeneca Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 AstraZeneca Recent Developments and Future Plans
2.5 Deltanoid
2.5.1 Deltanoid Details
2.5.2 Deltanoid Major Business
2.5.3 Deltanoid Late Stage Chronic Kidney Disease Drugs Product and Solutions
2.5.4 Deltanoid Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Deltanoid Recent Developments and Future Plans
2.6 Akebia Therapeutics
2.6.1 Akebia Therapeutics Details
2.6.2 Akebia Therapeutics Major Business
2.6.3 Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Product and Solutions
2.6.4 Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Akebia Therapeutics Recent Developments and Future Plans
2.7 Kyowa Hakko Kirin
2.7.1 Kyowa Hakko Kirin Details
2.7.2 Kyowa Hakko Kirin Major Business
2.7.3 Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Product and Solutions
2.7.4 Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Kyowa Hakko Kirin Recent Developments and Future Plans
2.8 OPKO Health
2.8.1 OPKO Health Details
2.8.2 OPKO Health Major Business
2.8.3 OPKO Health Late Stage Chronic Kidney Disease Drugs Product and Solutions
2.8.4 OPKO Health Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 OPKO Health Recent Developments and Future Plans
2.9 Vifor Pharma
2.9.1 Vifor Pharma Details
2.9.2 Vifor Pharma Major Business
2.9.3 Vifor Pharma Late Stage Chronic Kidney Disease Drugs Product and Solutions
2.9.4 Vifor Pharma Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Vifor Pharma Recent Developments and Future Plans
2.10 Sanofi
2.10.1 Sanofi Details
2.10.2 Sanofi Major Business
2.10.3 Sanofi Late Stage Chronic Kidney Disease Drugs Product and Solutions
2.10.4 Sanofi Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Sanofi Recent Developments and Future Plans
2.11 Shield Therapeutics
2.11.1 Shield Therapeutics Details
2.11.2 Shield Therapeutics Major Business
2.11.3 Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Product and Solutions
2.11.4 Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Shield Therapeutics Recent Developments and Future Plans
2.12 Shire
2.12.1 Shire Details
2.12.2 Shire Major Business
2.12.3 Shire Late Stage Chronic Kidney Disease Drugs Product and Solutions
2.12.4 Shire Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Shire Recent Developments and Future Plans
2.13 Spectrum
2.13.1 Spectrum Details
2.13.2 Spectrum Major Business
2.13.3 Spectrum Late Stage Chronic Kidney Disease Drugs Product and Solutions
2.13.4 Spectrum Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Spectrum Recent Developments and Future Plans
2.14 ZS Pharma
2.14.1 ZS Pharma Details
2.14.2 ZS Pharma Major Business
2.14.3 ZS Pharma Late Stage Chronic Kidney Disease Drugs Product and Solutions
2.14.4 ZS Pharma Late Stage Chronic Kidney Disease Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 ZS Pharma Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Late Stage Chronic Kidney Disease Drugs Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Late Stage Chronic Kidney Disease Drugs Players Market Share
3.2.2 Top 10 Late Stage Chronic Kidney Disease Drugs Players Market Share
3.2.3 Market Competition Trend
3.3 Late Stage Chronic Kidney Disease Drugs Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Late Stage Chronic Kidney Disease Drugs Revenue and Market Share by Type (2016-2021)
4.2 Global Late Stage Chronic Kidney Disease Drugs Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Application (2016-2021)
5.2 Late Stage Chronic Kidney Disease Drugs Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Late Stage Chronic Kidney Disease Drugs Revenue by Type (2016-2026)
6.2 North America Late Stage Chronic Kidney Disease Drugs Revenue by Application (2016-2026)
6.3 North America Late Stage Chronic Kidney Disease Drugs Market Size by Country
6.3.1 North America Late Stage Chronic Kidney Disease Drugs Revenue by Country (2016-2026)
6.3.2 United States Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
6.3.3 Canada Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
6.3.4 Mexico Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Late Stage Chronic Kidney Disease Drugs Revenue by Type (2016-2026)
7.2 Europe Late Stage Chronic Kidney Disease Drugs Revenue by Application (2016-2026)
7.3 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Country
7.3.1 Europe Late Stage Chronic Kidney Disease Drugs Revenue by Country (2016-2026)
7.3.2 Germany Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
7.3.3 France Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
7.3.5 Russia Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
7.3.6 Italy Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Revenue by Type (2016-2026)
8.2 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Revenue by Application (2016-2026)
8.3 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Region
8.3.1 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Revenue by Region (2016-2026)
8.3.2 China Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
8.3.3 Japan Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
8.3.4 South Korea Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
8.3.5 India Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
8.3.7 Australia Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Late Stage Chronic Kidney Disease Drugs Revenue by Type (2016-2026)
9.2 South America Late Stage Chronic Kidney Disease Drugs Revenue by Application (2016-2026)
9.3 South America Late Stage Chronic Kidney Disease Drugs Market Size by Country
9.3.1 South America Late Stage Chronic Kidney Disease Drugs Revenue by Country (2016-2026)
9.3.2 Brazil Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
9.3.3 Argentina Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Revenue by Type (2016-2026)
10.2 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Revenue by Application (2016-2026)
10.3 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Country
10.3.1 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Revenue by Country (2016-2026)
10.3.2 Turkey Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
10.3.4 UAE Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Late Stage Chronic Kidney Disease Drugs Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Late Stage Chronic Kidney Disease Drugs Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Late Stage Chronic Kidney Disease Drugs Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Late Stage Chronic Kidney Disease Drugs Revenue (USD Million) by Region (2016-2021)
Table 5. Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Region (2021-2026)
Table 6. AbbVie Corporate Information, Head Office, and Major Competitors
Table 7. AbbVie Major Business
Table 8. AbbVie Late Stage Chronic Kidney Disease Drugs Product and Solutions
Table 9. AbbVie Late Stage Chronic Kidney Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Amgen Corporate Information, Head Office, and Major Competitors
Table 11. Amgen Major Business
Table 12. Amgen Late Stage Chronic Kidney Disease Drugs Product and Solutions
Table 13. Amgen Late Stage Chronic Kidney Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Ardelyx Corporate Information, Head Office, and Major Competitors
Table 15. Ardelyx Major Business
Table 16. Ardelyx Late Stage Chronic Kidney Disease Drugs Product and Solutions
Table 17. Ardelyx Late Stage Chronic Kidney Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 19. AstraZeneca Major Business
Table 20. AstraZeneca Late Stage Chronic Kidney Disease Drugs Product and Solutions
Table 21. AstraZeneca Late Stage Chronic Kidney Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Deltanoid Corporate Information, Head Office, and Major Competitors
Table 23. Deltanoid Major Business
Table 24. Deltanoid Late Stage Chronic Kidney Disease Drugs Product and Solutions
Table 25. Deltanoid Late Stage Chronic Kidney Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Akebia Therapeutics Corporate Information, Head Office, and Major Competitors
Table 27. Akebia Therapeutics Major Business
Table 28. Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Product and Solutions
Table 29. Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Kyowa Hakko Kirin Corporate Information, Head Office, and Major Competitors
Table 31. Kyowa Hakko Kirin Major Business
Table 32. Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Product and Solutions
Table 33. Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. OPKO Health Corporate Information, Head Office, and Major Competitors
Table 35. OPKO Health Major Business
Table 36. OPKO Health Late Stage Chronic Kidney Disease Drugs Product and Solutions
Table 37. OPKO Health Late Stage Chronic Kidney Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Vifor Pharma Corporate Information, Head Office, and Major Competitors
Table 39. Vifor Pharma Major Business
Table 40. Vifor Pharma Late Stage Chronic Kidney Disease Drugs Product and Solutions
Table 41. Vifor Pharma Late Stage Chronic Kidney Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Sanofi Corporate Information, Head Office, and Major Competitors
Table 43. Sanofi Major Business
Table 44. Sanofi Late Stage Chronic Kidney Disease Drugs Product and Solutions
Table 45. Sanofi Late Stage Chronic Kidney Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Shield Therapeutics Corporate Information, Head Office, and Major Competitors
Table 47. Shield Therapeutics Major Business
Table 48. Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Product and Solutions
Table 49. Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Shire Corporate Information, Head Office, and Major Competitors
Table 51. Shire Major Business
Table 52. Shire Late Stage Chronic Kidney Disease Drugs Product and Solutions
Table 53. Shire Late Stage Chronic Kidney Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Spectrum Corporate Information, Head Office, and Major Competitors
Table 55. Spectrum Major Business
Table 56. Spectrum Late Stage Chronic Kidney Disease Drugs Product and Solutions
Table 57. Spectrum Late Stage Chronic Kidney Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. ZS Pharma Corporate Information, Head Office, and Major Competitors
Table 59. ZS Pharma Major Business
Table 60. ZS Pharma Late Stage Chronic Kidney Disease Drugs Product and Solutions
Table 61. ZS Pharma Late Stage Chronic Kidney Disease Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Global Late Stage Chronic Kidney Disease Drugs Revenue (USD Million) by Players (2019-2021)
Table 63. Global Late Stage Chronic Kidney Disease Drugs Revenue Share by Players (2019-2021)
Table 64. Breakdown of Late Stage Chronic Kidney Disease Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 65. Late Stage Chronic Kidney Disease Drugs Players Head Office, Products and Services Provided
Table 66. Late Stage Chronic Kidney Disease Drugs Mergers & Acquisitions in the Past Five Years
Table 67. Late Stage Chronic Kidney Disease Drugs New Entrants and Expansion Plans
Table 68. Global Late Stage Chronic Kidney Disease Drugs Revenue (USD Million) by Type (2016-2021)
Table 69. Global Late Stage Chronic Kidney Disease Drugs Revenue Share by Type (2016-2021)
Table 70. Global Late Stage Chronic Kidney Disease Drugs Revenue Forecast by Type (2021-2026)
Table 71. Global Late Stage Chronic Kidney Disease Drugs Revenue by Application (2016-2021)
Table 72. Global Late Stage Chronic Kidney Disease Drugs Revenue Forecast by Application (2021-2026)
Table 73. North America Late Stage Chronic Kidney Disease Drugs Revenue by Type (2016-2021) & (USD Million)
Table 74. North America Late Stage Chronic Kidney Disease Drugs Revenue by Type (2021-2026) & (USD Million)
Table 75. North America Late Stage Chronic Kidney Disease Drugs Revenue by Application (2016-2021) & (USD Million)
Table 76. North America Late Stage Chronic Kidney Disease Drugs Revenue by Application (2021-2026) & (USD Million)
Table 77. North America Late Stage Chronic Kidney Disease Drugs Revenue by Country (2016-2021) & (USD Million)
Table 78. North America Late Stage Chronic Kidney Disease Drugs Revenue by Country (2021-2026) & (USD Million)
Table 79. Europe Late Stage Chronic Kidney Disease Drugs Revenue by Type (2016-2021) & (USD Million)
Table 80. Europe Late Stage Chronic Kidney Disease Drugs Revenue by Type (2021-2026) & (USD Million)
Table 81. Europe Late Stage Chronic Kidney Disease Drugs Revenue by Application (2016-2021) & (USD Million)
Table 82. Europe Late Stage Chronic Kidney Disease Drugs Revenue by Application (2021-2026) & (USD Million)
Table 83. Europe Late Stage Chronic Kidney Disease Drugs Revenue by Country (2016-2021) & (USD Million)
Table 84. Europe Late Stage Chronic Kidney Disease Drugs Revenue by Country (2021-2026) & (USD Million)
Table 85. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Revenue by Type (2016-2021) & (USD Million)
Table 86. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Revenue by Type (2021-2026) & (USD Million)
Table 87. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Revenue by Application (2016-2021) & (USD Million)
Table 88. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Revenue by Application (2021-2026) & (USD Million)
Table 89. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Revenue by Region (2016-2021) & (USD Million)
Table 90. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Revenue by Region (2021-2026) & (USD Million)
Table 91. South America Late Stage Chronic Kidney Disease Drugs Revenue by Type (2016-2021) & (USD Million)
Table 92. South America Late Stage Chronic Kidney Disease Drugs Revenue by Type (2021-2026) & (USD Million)
Table 93. South America Late Stage Chronic Kidney Disease Drugs Revenue by Application (2016-2021) & (USD Million)
Table 94. South America Late Stage Chronic Kidney Disease Drugs Revenue by Application (2021-2026) & (USD Million)
Table 95. South America Late Stage Chronic Kidney Disease Drugs Revenue by Country (2016-2021) & (USD Million)
Table 96. South America Late Stage Chronic Kidney Disease Drugs Revenue by Country (2021-2026) & (USD Million)
Table 97. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Revenue by Type (2016-2021) & (USD Million)
Table 98. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Revenue by Type (2021-2026) & (USD Million)
Table 99. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Revenue by Application (2016-2021) & (USD Million)
Table 100. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Revenue by Application (2021-2026) & (USD Million)
Table 101. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Revenue by Country (2016-2021) & (USD Million)
Table 102. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Late Stage Chronic Kidney Disease Drugs Picture
Figure 2. Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Type in 2020
Figure 3. Calcimimetics
Figure 4. Vitamin D Sterols
Figure 5. Potassium Binders
Figure 6. Others
Figure 7. Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Application in 2020
Figure 8. Hospital Pharmacies Picture
Figure 9. Online Pharnacies Picture
Figure 10. Retail Pharmacies Picture
Figure 11. Global Late Stage Chronic Kidney Disease Drugs Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 12. Global Late Stage Chronic Kidney Disease Drugs Revenue and Forecast (2016-2026) & (USD Million)
Figure 13. Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Region (2016-2026)
Figure 14. Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Region in 2020
Figure 15. North America Late Stage Chronic Kidney Disease Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Europe Late Stage Chronic Kidney Disease Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. South America Late Stage Chronic Kidney Disease Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Middle East and Africa Late Stage Chronic Kidney Disease Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Late Stage Chronic Kidney Disease Drugs Market Drivers
Figure 21. Late Stage Chronic Kidney Disease Drugs Market Restraints
Figure 22. Late Stage Chronic Kidney Disease Drugs Market Trends
Figure 23. AbbVie Recent Developments and Future Plans
Figure 24. Amgen Recent Developments and Future Plans
Figure 25. Ardelyx Recent Developments and Future Plans
Figure 26. AstraZeneca Recent Developments and Future Plans
Figure 27. Deltanoid Recent Developments and Future Plans
Figure 28. Akebia Therapeutics Recent Developments and Future Plans
Figure 29. Kyowa Hakko Kirin Recent Developments and Future Plans
Figure 30. OPKO Health Recent Developments and Future Plans
Figure 31. Vifor Pharma Recent Developments and Future Plans
Figure 32. Sanofi Recent Developments and Future Plans
Figure 33. Shield Therapeutics Recent Developments and Future Plans
Figure 34. Shire Recent Developments and Future Plans
Figure 35. Spectrum Recent Developments and Future Plans
Figure 36. ZS Pharma Recent Developments and Future Plans
Figure 37. Global Late Stage Chronic Kidney Disease Drugs Revenue Share by Players in 2020
Figure 38. Late Stage Chronic Kidney Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 39. Global Top 3 Players Late Stage Chronic Kidney Disease Drugs Revenue Market Share in 2020
Figure 40. Global Top 10 Players Late Stage Chronic Kidney Disease Drugs Revenue Market Share in 2020
Figure 41. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 42. Global Late Stage Chronic Kidney Disease Drugs Revenue Share by Type in 2020
Figure 43. Global Late Stage Chronic Kidney Disease Drugs Market Share Forecast by Type (2021-2026)
Figure 44. Global Late Stage Chronic Kidney Disease Drugs Revenue Share by Application in 2020
Figure 45. Global Late Stage Chronic Kidney Disease Drugs Market Share Forecast by Application (2021-2026)
Figure 46. North America Late Stage Chronic Kidney Disease Drugs Sales Market Share by Type (2016-2026)
Figure 47. North America Late Stage Chronic Kidney Disease Drugs Sales Market Share by Application (2016-2026)
Figure 48. North America Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Country (2016-2026)
Figure 49. United States Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Canada Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Mexico Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Europe Late Stage Chronic Kidney Disease Drugs Sales Market Share by Type (2016-2026)
Figure 53. Europe Late Stage Chronic Kidney Disease Drugs Sales Market Share by Application (2016-2026)
Figure 54. Europe Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Country (2016-2026)
Figure 55. Germany Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. France Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. United Kingdom Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Russia Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Italy Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Sales Market Share by Type (2016-2026)
Figure 61. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Sales Market Share by Application (2016-2026)
Figure 62. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Region (2016-2026)
Figure 63. China Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Japan Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South Korea Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. India Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Southeast Asia Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Australia Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. South America Late Stage Chronic Kidney Disease Drugs Sales Market Share by Type (2016-2026)
Figure 70. South America Late Stage Chronic Kidney Disease Drugs Sales Market Share by Application (2016-2026)
Figure 71. South America Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Country (2016-2026)
Figure 72. Brazil Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Argentina Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Middle East and Africa Late Stage Chronic Kidney Disease Drugs Sales Market Share by Type (2016-2026)
Figure 75. Middle East and Africa Late Stage Chronic Kidney Disease Drugs Sales Market Share by Application (2016-2026)
Figure 76. Middle East and Africa Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Country (2016-2026)
Figure 77. Turkey Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Saudi Arabia Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. UAE Late Stage Chronic Kidney Disease Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Methodology
Figure 81. Research Process and Data Source

---